| |
Hypertension
| |
Dyslipidemia
|
---|
|
N
|
Without anti-hypertensive medication n (%)
|
Unadjusted
|
Adjusted for Age, Sex, BMI, MI, Stroke, Study
|
N
|
Without lipid lowering medication n (%)
|
Unadjusted
|
Adjusted for Sex, MI
|
---|
|
1048
|
226 (21.6)
|
OR (95%CI)
|
OR (95%CI)
|
636
|
396 (62.3)
|
OR (95%CI)
|
OR (95%CI)
|
---|
Age in years
|
70-74
|
257
|
38 (14.8)
|
Reference
|
Reference
|
134
|
84 (62.7)
|
Reference
|
Reference
|
65-69
|
252
|
49 (19.4)
|
1.39 (0.87-2.21)
|
1.35 (0.83-2.19)
|
146
|
81 (55.5)
|
0.74 (0.46-1.20)
|
0.71 (0.43-1.16)
|
60-64
|
254
|
57 (22.4)
|
1.67 (1.06-2.62)
|
1.46 (0.90-2.35)
|
157
|
97 (61.8)
|
0.96 (0.60-1.55)
|
0.94 (0.57-1.54)
|
55-59
|
151
|
41 (27.2)
|
2.15 (1.31-3.53)
|
1.80 (1.06-3.05)
|
98
|
63 (64.3)
|
1.07 (0.62-1.84)
|
0.93 (0.53-1.63)
|
45-54
|
134
|
41 (30.6)
|
2.54 (1.54-4.20)
|
2.28 (1.34-3.90)
|
101
|
71 (70.3)
|
1.41 (0.81-2.45)
|
1.10 (0.62-1.95)
|
Sex
|
Male
|
563
|
153 (27.2)
|
2.11 (1.54-2.87)
|
2.11 (1.52-2.93)
|
362
|
246 (68.0)
|
1.75 (1.27-2.43)
|
2.02 (1.44-2.84)
|
Female
|
485
|
73 (15.1)
|
Reference
|
Reference
|
274
|
150 (54.7)
|
Reference
|
Reference
|
Smoking
|
Yes
|
150
|
46 (30.7)
|
1.80 (1.22-2.64)
|
1.40 (0.92-2.13)
|
115
|
80 (69.6)
|
1.49 (0.96-2.30)
|
1.30 (0.82-2.04)
|
No
|
880
|
174 (19.8)
|
Reference
|
Reference
|
510
|
309 (60.6)
|
Reference
|
Reference
|
BMI
|
> = 30
|
546
|
86 (15.8)
|
Reference
|
Reference
|
322
|
199 (61.8)
|
Reference
|
Reference
|
<30
|
500
|
139 (27.8)
|
2.06 (1.52-2.79)
|
1.98 (1.43-2.74)
|
312
|
195 (62.5)
|
1.03 (0.75-1.42)
|
0.89 (0.63-1.24)
|
Physical inactivity
|
Yes
|
757
|
160 (21.1)
|
Reference
|
Reference
|
461
|
298 (64.6)
|
1.42 (0.99-2.04)
|
1.49 (1.03-2.17)
|
No
|
280
|
64 (22.9)
|
1.11 (0.80-1.54)
|
1.10 (0.77-1.56)
|
167
|
94 (56.3)
|
Reference
|
Reference
|
School education
|
Low
|
811
|
168 (20.7)
|
Reference
|
Reference
|
499
|
308 (61.7)
|
Reference
|
Reference
|
High and middle
|
221
|
54 (24.4)
|
1.24 (0.87-1.76)
|
1.08 (0.74-1.58)
|
126
|
82 (65.1)
|
1.16 (0.77-1.74)
|
0.98 (0.64-1.50)
|
Income
|
Low
|
162
|
37 (22.8)
|
Reference
|
Reference
|
104
|
65 (62.5)
|
Reference
|
Reference
|
Middle
|
674
|
133 (19.7)
|
0.83 (0.55-1.26)
|
0.73 (0.47-1.14)
|
405
|
248 (61.2)
|
0.95 (0.61-1.48)
|
0.92 (0.58-1.47)
|
High
|
109
|
31 (28.4)
|
1.34 (0.77-2.34)
|
0.90 (0.49-1.65)
|
62
|
45 (72.6)
|
1.59 (0.80-3.15)
|
1.17 (0.57-2.39)
|
Myocardial infarction
|
Yes
|
107
|
8 (7.5)
|
Reference
|
Reference
|
89
|
34 (38.2)
|
Reference
|
Reference
|
No
|
934
|
217 (23.2)
|
3.75 (1.79-7.82)
|
3.65 (1.72 -7.75)
|
540
|
357 (66.1)
|
3.16 (1.99-5.01)
|
3.62 (2.25-5.82)
|
Stroke
|
Yes
|
81
|
7 (8.6)
|
Reference
|
Reference
|
48
|
29 (60.4)
|
Reference
|
Reference
|
No
|
960
|
219 (22.8)
|
3.12 (1.42-6.88)
|
3.45 (1.53-7.79)
|
585
|
366 (62.6)
|
1.10 (0.60-2.00)
|
0.99 (0.52-1.85)
|
Dyslipidemia
|
Hypertension
|
Yes
|
530
|
109 (20.6)
|
Reference
|
Reference
|
530
|
322 (60.8)
|
Reference
|
Reference
|
No
|
426
|
97 (22.8)
|
1.14 (0.84-1.55)
|
1.15 (0.83-1.60)
|
105
|
74 (70.5)
|
1.54 (0.98-2.43)
|
1.71 (1.06-2.78)
|
Study
|
GNHIES98
|
228
|
65 (28.5)
|
Reference
|
Reference
|
155
|
102 (65.8)
|
Reference
|
Reference
|
CARLA
|
155
|
22 (14.2)
|
0.42 (0.24-0.71)
|
0.39 (0.22-0.69)
|
84
|
46 (54.8)
|
0.63 (0.37-1.08)
|
0.56 (0.32-0.98)
|
DHS
|
73
|
17 (23.3)
|
0.76 (0.41-1.41)
|
0.91 (0.47-1.74)
|
-
|
-
|
-
|
-
|
KORA
|
114
|
24 (21.1)
|
0.67 (0.39-1.14)
|
0.82 (0.46-1.45)
|
80
|
52 (65.0)
|
0.97 (0.55-1.70)
|
0.95 (0.53-1.72)
|
HNR
|
263
|
51 (19.4)
|
0.60 (0.40-0.92)
|
0.60 (0.39-0.93)
|
174
|
101 (58.1)
|
0.72 (0.46-1.13)
|
0.68 (0.42-1.08)
|
SHIP
|
215
|
47 (21.9)
|
0.70 (0.46-1.08)
|
0.73 (0.46-1.16)
|
143
|
95 (66.4)
|
1.03 (0.64-1.66)
|
1.08 (0.65-1.79)
|
- No pharmacotherapy for hypertension – Age, Sex, BMI, MI, Stroke, Study: ROC = 0.71, Hosmer-Lemeshow p-value = 0.46.
- No pharmacotherapy for dyslipidemia – Sex, MI: ROC = 0.64, Hosmer-Lemeshow p-value = 0.62.